Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Shionogi Launches 4th-Dose COVID Jab Trial for Ages 60-Plus
July 27, 2022
- Mitsubishi Tanabe to Terminate Human Serum Albumin Business
July 26, 2022
- Enhertu Gets FDA’s Priority Review for HER2 Low Breast Cancer
July 26, 2022
- BMS Has High Hopes on Eliquis Follow-Up with Less Bleeding Risks as Patent Loss Looms
July 26, 2022
- Takeda’s Hyqvia Smashes Primary Goal in Global PIII for CIDP
July 25, 2022
- Otsuka Gets EU Panel Backing for Lupus Nephritis Drug
July 25, 2022
- Keytruda, Opdivo, Tagrisso Breach 100 Billion Yen Sales Mark in FY2021: Tally
July 22, 2022
- Daiichi Sankyo Launches Global PII to Test ADC DS-7300 for SCLC
July 22, 2022
- Chugai Enjoys Big Surge in H1 Earnings on Strong Uptake of New Launches
July 22, 2022
- Shionogi to Steadily Promote PIII Trial for COVID Pill after Approval Setback
July 22, 2022
- Gene Therapy VB-111 Fails in PIII Ovarian Cancer Trial: NanoCarrier
July 21, 2022
- JT’s Tapinarof Cream Safe and Effective for Eczema: Japan PIII Study
July 21, 2022
- Texas Court Favors Seagen in Enhertu Patent Row, Daiichi Sankyo Poised to Challenge Ruling
July 21, 2022
- Healios to Raise 2.9 Billion Yen for R&D of eNK Cells
July 20, 2022
- Ono Sets Up Venture Capital Unit to Invest in Digital Health
July 20, 2022
- Opdivo Approved in Taiwan for Frontline Esophageal Cancer Use
July 20, 2022
- Enhertu Gets 2nd Line Breast Cancer Nod in Europe: Daiichi Sankyo
July 20, 2022
- Shionogi Begins COVID-19 Vaccine Trial in Children Aged 5-11
July 20, 2022
- Konica Minolta’s Cancer Genomic Profiling System Approved in Japan
July 19, 2022
- Kyowa Kirin to Cease Development of Parkinson’s Hopeful KW-6356
July 19, 2022
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…